## **ARTICLES**

## L-Ascorbic Acid Represses Constitutive Activation of NF-кВ and COX-2 Expression in Human Acute Myeloid Leukemia, HL-60

112

Seong-Su Han,<sup>1</sup> Kihyun Kim,<sup>1</sup> Eun-Ryeong Hahm,<sup>1</sup> Sook J. Lee,<sup>1</sup> Young-Joon Surh,<sup>2</sup> Hye K. Park,<sup>1</sup> Won S. Kim,<sup>1</sup> Chul W. Jung,<sup>1</sup> Mark H. Lee,<sup>1</sup> Keunchil Park,<sup>1</sup> Jung-Hyun Yang,<sup>1</sup> Sung-Soo Yoon,<sup>1,3</sup> Neil H. Riordan,<sup>4</sup> Hugh D. Riordan,<sup>5</sup> Bruce F. Kimler,<sup>6</sup> Chan H. Park,<sup>1,4,5</sup> Je-Ho Lee,<sup>1\*</sup> and Seyeon Park<sup>1,7\*</sup>

<sup>1</sup>Samsung Medical Center, and Sungkyunkwan University School of Medicine, Seoul 135-710, Korea

<sup>2</sup>College of Pharmacy, Seoul National University, Seoul 151-742, Korea

<sup>3</sup>Seoul National University College of Medicine, Seoul 110-799, Korea

<sup>4</sup>Aidan Incorporated, Tempe, Arizona 85281

<sup>5</sup>The Center for the Improvement of Human Functioning International, Wichita, Kansas 67219

<sup>6</sup>University of Kansas Medical Center, Kansas City, Kansas 66160

<sup>7</sup>Anesthesia and Pain Research Institute, Yonsei University College of Medicine, Seoul 120-752, Korea

Abstract There is increasing evidence that L-ascorbic acid (LAA) is selectively toxic to some types of cancer cells at pharmacological concentrations, functioning as a pro-oxidant rather than as an anti-oxidant. However, the molecular mechanisms by which LAA initiates cellular signaling leading to cell death are still unclear. In an effort to gain insight into these mechanisms, the effects of LAA on eukaryotic transcription nuclear factor NF-κB and cyclooxygenase-2 (COX-2) expression were investigated. In the present study, LAA suppressed DNA binding activity of NF-κB, composed of a p65/p50 heterodimer, through inhibition of degradation of inhibitory  $\kappa$ B-α ( $l\kappa$ B-α) and prevention of nuclear translocation of p65. The inhibitory effect of LAA on NF-κB activity was dependent upon glutathione levels in HL-60 cells, as well as generation of H<sub>2</sub>O<sub>2</sub> but not superoxide anion. LAA also downregulated the expression of COX-2, which has a NF-κB binding site on its promoter, through repressing NF-κB DNA binding activity. Moreover, cotreatment of 1  $\mu$ M arsenic trioxide (As<sub>2</sub>O<sub>3</sub>) with various concentrations of LAA enhanced an LAA-induced repression of NF-κB activity and COX-2 expression. In conclusion, our data suggest that LAA exerts its anti-tumor activity through downregulation of NF-κB activity and COX-2 expression, and these inhibitory effects can be enhanced by co-treatment with As<sub>2</sub>O<sub>3</sub>. J. Cell. Biochem. 93: 257–270, 2004. © 2004 Wiley-Liss, Inc.

Key words: ι-ascorbic acid; NF-κB; COX-2; arsenic; acute myeloid leukemia

L-Ascorbic acid (LAA) is one of the major water-soluble anti-oxidants present in cells and plasma. There are other studies demonstrating that under certain conditions LAA acts as a prooxidant and increases DNA damage [Stich et al.,

1976; Speit et al., 1980]. Also, there is increasing evidence that LAA is selectively toxic to some types of tumor, functioning as a pro-oxidant rather than as an anti-oxidant [Bram et al., 1980; Bruchelt et al., 1993]. LAA at concentra-

\*Correspondence to: Je-Ho Lee, MD, PhD, and Seveon

Park, PhD, Cancer Center, Samsung Medical Center

Annex Building 8th Fl. Ilwon-Dong, Kangnam-Ku, Seoul

Abbreviations used: AML, acute myeloid leukemia; As<sub>2</sub>O<sub>3</sub>, arsenic trioxide; BSO, buthionine sulfoximine; COX-2, cyclooxygenase-2; DHA, dehydroascorbic acid; DMSO, dimethyl sulfoxide; DTT, dithiolthreitol; EMSA, electrophoresis mobility shift assay; ERK, extracellular signal-regulated kinases; FBS, fetal bovine serum; GSH, glutathione; IκB-α, inhibitory κB-α; LAA, L-ascorbic acid; NF-κB, nuclear factor κB; JNK, c-Jun N-terminal kinases; NaN<sub>3</sub>, sodium azide; PBS, phosphate-buffered saline; PMSF, phenylmethylsulfonyl fluoride; ROS, reactive oxygen species; SBA, sodium 5,6-benzylidene-L-ascorbate; SOD, superoxide dismutase; TPCK, N-tosyl-L-phenylalanine chloromethyl ketone.

Published online 29 June 2004 in Wiley InterScience (www.interscience.wiley.com).

Grant sponsor: Jin Yang Pharmaceutical Co., Ltd.

135-710, Korea. E-mail: seypark21@hotmail.com

Received 8 January 2004; Accepted 1 March 2004

DOI 10.1002/jcb.20116

© 2004 Wiley-Liss, Inc.